Precision Medicine in Oncology

The AJMC® Precision Medicine in Oncology compendium is a comprehensive resource for clinical news and expert insights for molecular profiling of tumors.

Latest News

There was significant variability in test frequency and detection rates among patients with AML and MDS. | Image credit: Saiful52-stock.adobe.com
Gaps in Molecular Testing Rates, Targeted Treatment Persist in MDS, AML

July 11th 2025

There are molecular testing gaps in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treatment, highlighting the need for improved testing and targeted therapy integration.

DNA | Image credit: NHS
Breast Cancer and the Use of Predictive Genomics

June 18th 2025

May 2024 News From Strategic Alliance Partners
May 2024 News From Strategic Alliance Partners

May 20th 2024

New KRYSTAL-1 Data Show 90% Intracranial Disease Control Rate in Patients With KRAS G12C–Mutated NSCLC and Untreated CNS Metastases
New KRYSTAL-1 Data Show 90% Intracranial Disease Control Rate in Patients With KRAS G12C–Mutated NSCLC and Untreated CNS Metastases

August 16th 2023

ASCO 2023 logo
ASCO 2023: Solid Tumors

July 31st 2023

More News

Dr John Fox Emphasizes the Importance of Genetic Counseling Before, After Genetic Testing
September 3rd 2019

Dr John Fox Emphasizes the Importance of Genetic Counseling Before, After Genetic Testing

Offering patients genetic counseling before and after they receive genetic testing is crucial for making sure they understand what the results mean, explained John Fox, MD, MHA, vice president of Clinical Transformation at Spectrum Health.
Dr Ajai Chari Explains MGUS and How to Discuss It With Patients
August 31st 2019

Dr Ajai Chari Explains MGUS and How to Discuss It With Patients

Monoclonal gammopathy of undetermined significance is a diagnosis of exclusion, but even once it has been identified, patients should not obsess over this precancerous condition, said Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital.
Researchers Test Approach to Remove Protective Tumor Barrier, Making Immunotherapies More Effective
August 30th 2019

Researchers Test Approach to Remove Protective Tumor Barrier, Making Immunotherapies More Effective

Jaime Rosenberg
While the results are early, if further research proves the approach effective, it could help boost the impact of treatments like chimeric antigen receptor (CAR) T-cell therapy, which to date hasn’t had much luck in solid tumors.
This Week in Managed Care: August 23, 2019
August 23rd 2019

This Week in Managed Care: August 23, 2019

This week in managed care, the top news included outcomes results in treating heart failure; US prevention experts said more women should get BRCA testing; the American Heart Association offered an advisory on treating high triglycerides with prescription omega-3 fatty acids.
More Women May Be Screened for BRCA Mutations Following USPSTF Guideline Update
August 21st 2019

More Women May Be Screened for BRCA Mutations Following USPSTF Guideline Update

Jaime Rosenberg
The update to the 2013 recommendation includes a grade B recommendation that women with a personal history of breast, ovarian, tubal, or peritoneal cancer, and women with ancestry associated with BRCA1/2 mutations be assessed for the genetic mutations.
MDM2 Antagonists Help CDK4/6 Inhibitors Overcome Resistance in Melanoma
August 21st 2019

MDM2 Antagonists Help CDK4/6 Inhibitors Overcome Resistance in Melanoma

Laura Joszt, MA
Outside of breast cancer, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have not been as successful as tumors develop resistance. New research shows that a murine double minute (MDM2) antagonist can help CDK4/6 inhibitors overcome resistance, offering a potential second-line treatment option in melanoma.
Palbociclib and Crizotinib More Effective When Paired Together
August 15th 2019

Palbociclib and Crizotinib More Effective When Paired Together

Laura Joszt, MA
Researchers showed the potential of combining 2 precision medicines to overcome treatment resistance.
Site Logo
August 13th 2019

COTA Collaboration: Helping FDA Figure Out What's Possible and What's Not in Embrace of Real-World Evidence

Mary Caffrey
A Conversation With Chief Medical Officer Andrew Norden, MD, MPH, MBA
Dr John Fox Discusses Expanding Comprehensive Genomic Profiling Across Several Cancers
August 12th 2019

Dr John Fox Discusses Expanding Comprehensive Genomic Profiling Across Several Cancers

John Fox, MD, MHA, vice president of Clinical Transformation at Spectrum Health, reacts to the National Comprehensive Cancer Network's call to expand comprehensive genomic testing across several cancers.
New Understanding of PARP Inhibitors Could Expand the Number of Patients to Treat
August 9th 2019

New Understanding of PARP Inhibitors Could Expand the Number of Patients to Treat

Laura Joszt, MA
A new understanding of how poly (ADP ribose) polymerase (PARP) inhibitors work could expand the patient populations who are treated, according to a study. The researchers also identified a potential biomarker to indicate which patients would benefit the most.
New York Approves NGS-Based Test to Detect, Monitor MRD in Certain Blood Cancers
August 6th 2019

New York Approves NGS-Based Test to Detect, Monitor MRD in Certain Blood Cancers

Jaime Rosenberg
Following the state's approval, the ClonoSEQ Assay will be available in all 50 states.
Underlying Pathway in Lung Cancer Could Identify Appropriate Targeted Treatments
August 3rd 2019

Underlying Pathway in Lung Cancer Could Identify Appropriate Targeted Treatments

Laura Joszt, MA
Research has uncovered 2 pathways through which lung adenocarcinoma can develop, and that knowledge could help target treatments to patients who will benefit the most, according to a new study published in Cancer Cell.
Dr John Fox on the Economic Value of Comprehensive Genomic Profiling
July 31st 2019

Dr John Fox on the Economic Value of Comprehensive Genomic Profiling

Whether or not there is economic value of comprehensive genomic profiling likely depends on what tissue type and what tumor type we’re talking about, explained John Fox, MD, MHA, vice president of Clinical Transformation at Spectrum Health.
Gut Microbiome Associated With Minimal Residual Disease Negativity in Multiple Myeloma
July 23rd 2019

Gut Microbiome Associated With Minimal Residual Disease Negativity in Multiple Myeloma

Jaime Rosenberg
A new study is indicating that microbiota composition in the gut could have implications for treatment response in multiple myeloma.
Sue Friedman Outlines Misconceptions Regarding Genetic Testing in Cancer
July 23rd 2019

Sue Friedman Outlines Misconceptions Regarding Genetic Testing in Cancer

Many people associate the BRCA mutations with breast and ovarian cancer and mistakenly think they, and other genes that contribute to cancer, don’t affect men, said Sue Friedman, DVM, executive director of FORCE: Facing Our Risk of Cancer Empowered.
Strategic Alliance Focuses on Using Precision Medicine to Transform Healthcare Delivery
July 20th 2019

Strategic Alliance Focuses on Using Precision Medicine to Transform Healthcare Delivery

AJMC Staff
A new initiative seeking to transform healthcare delivery will elevate precision medicine with a focus on cancer, Alzheimer disease, cardiovascular disease, and more.
Personalized Cancer Vaccine Yields Promising Results for Patients With High-Risk Melanoma
July 18th 2019

Personalized Cancer Vaccine Yields Promising Results for Patients With High-Risk Melanoma

Jaime Rosenberg
A phase 2b clinical trial is producing promising results for a personalized cancer vaccine used in patients with stage III and IV resected melanoma.
Neil Goldfarb Discusses Employers Covering Precision Medicines
July 13th 2019

Neil Goldfarb Discusses Employers Covering Precision Medicines

As expensive precision medicines come to market, employers are willing to cover the costs if these medicines are shown to work and improve patient experience or outcome, said Neil Goldfarb, president and chief executive officer of the Greater Philadelphia Business Group on Health.
Blinatumomab Reduces MRD Prior to HCT in Pediatric Patients With B-ALL
July 10th 2019

Blinatumomab Reduces MRD Prior to HCT in Pediatric Patients With B-ALL

Jaime Rosenberg
Pediatric patients with relapsed or refractory B acute lymphoblastic leukemia (B-ALL) with minimal residual disease (MRD) who were treated with blinatumomab proceeded to hematopoietic cell transplant (HCT) without delay and had limited side effects.
Undetectable MRD Status in Patients With CLL
July 1st 2019

Undetectable MRD Status in Patients With CLL

Laura Joszt, MA
Achieving undetectable minimal residual disease (MRD) status is important for deep and durable responses in patients with chronic lymphocytic leukemia (CLL), according to 2 abstracts presented at the 2019 American Society of Clinical Oncology Annual Meeting.
Assessing MRD Status in Patients With MM By Risk Status
June 29th 2019

Assessing MRD Status in Patients With MM By Risk Status

Laura Joszt, MA
While minimal residual disease (MRD) is being used to assess response to treatment in multiple myeloma (MM), the level of risk a patient has can make a big different in how well MRD works as a prognostic indicator, according to 2 abstracts presented at the 2019 American Society of Clinical Oncology Annual Meeting.
Dr Jeanne Tie Outlines How a Blood Test Can Detect Early Stages of Cancer
June 25th 2019

Dr Jeanne Tie Outlines How a Blood Test Can Detect Early Stages of Cancer

A new blood test being worked on can detect 8 common cancer types in a way that is less invasive than other tests, said Jeanne Tie, MBChB, FRACP, MD, medical oncologist and associate professor at the Walter+Eliza Hall Institute of Medical Research.
Removing Barriers to Improve the Use of Diagnostic Tests for Precision Cancer Care
June 21st 2019

Removing Barriers to Improve the Use of Diagnostic Tests for Precision Cancer Care

Laura Joszt, MA
Currently, the number of patients who are actually utilizing precision cancer care treatments is small, but it is growing fast. As that happens, physicians will need to get comfortable with ordering the right tests, explained Clynt Taylor, chief executive officer of Intervention Insights, and Lee Newcomer, MD, formerly of UnitedHealth Group.
COTA, FDA Partner to Better Understand How to Tailor Cancer Treatments in the Real World
June 19th 2019

COTA, FDA Partner to Better Understand How to Tailor Cancer Treatments in the Real World

Laura Joszt, MA
The FDA is partnering with COTA, a precision medicine technology company, to gain better insight into treatment variation within subpopulations of patients using real-world data. The program will start with breast cancer and may expand to other cancer types.
Precision Medicine Trial Shows Drug Combination Is Effective in Rare Cancers
June 14th 2019

Precision Medicine Trial Shows Drug Combination Is Effective in Rare Cancers

Laura Joszt, MA
The results of the NCI-MATCH precision medicine trial showed that a drug combination designed to target cancers with certain BRAF gene mutations was effective.
Sue Friedman on Targeted Therapies and Knowing Family History of Cancer
June 13th 2019

Sue Friedman on Targeted Therapies and Knowing Family History of Cancer

Genetic testing and understanding family history of cancer is important because more and more targeted therapies are coming out that are designed to work with specific mutations or inherited forms of mutations, said Sue Friedman, DVM, executive director of FORCE: Facing Our Risk of Cancer Empowered.
Dr Jeanne Tie on How ctDNA Helps Guide Decisions in Cancer Care
June 8th 2019

Dr Jeanne Tie on How ctDNA Helps Guide Decisions in Cancer Care

Circulating tumor DNA (ctDNA) can now allow clinicians to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy, said Jeanne Tie, MBChB, FRACP, MD, medical oncologist and associate professor at the Walter+Eliza Hall Institute of Medical Research.
BRCA1/2 Mutation Status May Not Be Predictive of Checkpoint Inhibitor Response
June 3rd 2019

BRCA1/2 Mutation Status May Not Be Predictive of Checkpoint Inhibitor Response

Laura Joszt, MA
Contrary to conventional wisdom, higher levels of genomic instability have been associated with lower immunogenicity, which means drugs are less effective, in patients with BRCA1/2-related breast cancers, according to research published in Clinical Cancer Research.
Site Logo
June 3rd 2019

More From TAILORx: Adding Clinical Risk to Genomic Testing Can Guide Therapy Choices in Breast Cancer

Mary Caffrey
The follow-up to the landmark TAILORx trial shows that adding a clinical risk evaluation of the breast cancer tumor may have prognostic value; the authors' recommendations are drawn from other studies.
Site Logo
June 2nd 2019

Maintenance Olaparib Aids PFS in BRCA-Mutated Metastatic Pancreatic Cancer, but Not OS

Allison Inserro
Patients with advanced pancreatic cancer linked to germline genetic mutations did not see their disease worsen for an additional 3.6 months when treated with olaparib, but an early interim analysis did not show a statistically significant difference in overall survival (OS), according to study results presented Sunday at the American Society of Clinical Oncology Annual Meeting 2019.
<1
...
67891011121314>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo